User login
Key clinical point: Psoriatic arthritis with axial involvement (axPsA), defined either clinically or by imaging, showed distinct disease manifestations compared with axial spondyloarthritis (axSpA) plus psoriasis, indicating that axPsA and axSpA were distinct entities.
Major finding: Regardless of clinical or imaging definition used, patients with axPsA vs axSpA+psoriasis were significantly more often women and older individuals and less often human leucocyte antigen-B27 positive (all P < .05), as well as had more frequent peripheral manifestations (P < .001) but less frequent uveitis (P < .001).
Study details: Findings are from the RABBIT-SpA, a prospective longitudinal observational study, including 1395 patients with PsA (359 patients had axial involvement) and 1428 patients with axSpA (181 patients had psoriasis).
Disclosures: The study was supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris. The authors did not report conflicts of interest.
Source: Regierer AC et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: An analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837 (Mar 10). Doi: 10.1136/rmdopen-2022-002837.
Key clinical point: Psoriatic arthritis with axial involvement (axPsA), defined either clinically or by imaging, showed distinct disease manifestations compared with axial spondyloarthritis (axSpA) plus psoriasis, indicating that axPsA and axSpA were distinct entities.
Major finding: Regardless of clinical or imaging definition used, patients with axPsA vs axSpA+psoriasis were significantly more often women and older individuals and less often human leucocyte antigen-B27 positive (all P < .05), as well as had more frequent peripheral manifestations (P < .001) but less frequent uveitis (P < .001).
Study details: Findings are from the RABBIT-SpA, a prospective longitudinal observational study, including 1395 patients with PsA (359 patients had axial involvement) and 1428 patients with axSpA (181 patients had psoriasis).
Disclosures: The study was supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris. The authors did not report conflicts of interest.
Source: Regierer AC et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: An analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837 (Mar 10). Doi: 10.1136/rmdopen-2022-002837.
Key clinical point: Psoriatic arthritis with axial involvement (axPsA), defined either clinically or by imaging, showed distinct disease manifestations compared with axial spondyloarthritis (axSpA) plus psoriasis, indicating that axPsA and axSpA were distinct entities.
Major finding: Regardless of clinical or imaging definition used, patients with axPsA vs axSpA+psoriasis were significantly more often women and older individuals and less often human leucocyte antigen-B27 positive (all P < .05), as well as had more frequent peripheral manifestations (P < .001) but less frequent uveitis (P < .001).
Study details: Findings are from the RABBIT-SpA, a prospective longitudinal observational study, including 1395 patients with PsA (359 patients had axial involvement) and 1428 patients with axSpA (181 patients had psoriasis).
Disclosures: The study was supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris. The authors did not report conflicts of interest.
Source: Regierer AC et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: An analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837 (Mar 10). Doi: 10.1136/rmdopen-2022-002837.